Novel targets of current analgesic drug development

Jeffrey A. Katz*, Honorio T Benzon

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The development of new pharmaceutical agents for the treatment of pain seems at first like an ideal target for pharmaceutical companies. There is an enormous unmet need with a vast potential market. For many years, opioids and NSAIDs have remained the mainstay treatments in chronic pain, and while the advent of antiepileptic drugs and antidepressant medications into the indication arena for chronic and neuropathic pain has been helpful, it is far from adequate to meet the demands for controlling both acute and chronic pain. Hence, the pursuit of new novel medications for pain seems a rational action, but further insight shows how difficult the task truly is, not to mention the financial risks of such innovation.

Original languageEnglish (US)
Title of host publicationEssentials of Pharmacology for Anesthesia, Pain Medicine, and Critical Care
PublisherSpringer New York
Pages859-873
Number of pages15
ISBN (Electronic)9781461489481
ISBN (Print)9781461489474
DOIs
StatePublished - Jan 1 2015

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Novel targets of current analgesic drug development'. Together they form a unique fingerprint.

Cite this